top of page
Copilot_20260423_113308.png

Oncology Therapeutic Development 
Regulatory Policy Expertise

Navigating complex regulatory landscapes with professional precision and methodical guidance for the oncology therapeutics industry.

Multicolored Pills Closeup

Expertise in Clinical Regulatory Strategy

Consultation or public speaking

Pazdur Direct, headed by Dr. Richard Pazdur, provides unparalleled strategic guidance for oncology drug development and policy, bridging the gap between innovative science and the complex demands of global regulatory standards. Pazdur Direct navigates every stage of the medical and biologics compliance lifecycle with precision and methodical integrity. Dr. Pazdur is available to speak at select engagements. 

Pazdur 25th-152.JPG
Regulatory Strategy

Strategic guidance for navigating the complex IND, NDA, and BLA submission processes within the oncology space to ensure rapid market entry and compliance.

Policy Consulting

Rigorous assessments of regulatory filings and clinical trials to guarantee unwavering compliance with biologics industry standards and medical regulations.

Oncology Drug Development Advice 

Advice on the use of specialized pathways designed for biologics and oncology drugs, helping to optimize clinical data integrity while accelerating the timeline from bench to bedside. 

Decades of Oncology Drug Regulatory Expertise

Dr. Richard Pazdur is a leading figure in oncology drug regulation and the former Director of both the FDA’s Oncology Center of Excellence and the Center for Drug Evaluation and Research. Over his 26-year FDA career, he played a transformative role in modern cancer drug development, working closely with academic oncologists, industry partners, and regulatory scientists to streamline and strengthen the approval of innovative therapies.

 

At the FDA, Dr. Pazdur built one of the most effective and nationally respected oncology regulatory centers. He championed an integrated review model that improved cross-center coordination and accelerated the evaluation of novel cancer treatments. His leadership not only advanced scientific rigor but also created clearer, more predictable pathways for oncology drug development. A mentor to generations of regulators, he significantly influenced how cancer therapies are reviewed and how regulatory science evolves to meet emerging medical needs.

REGULATORY FILING ACCURACY

96%

YEARS OF ONCOLOGY LEADERSHIP

30+

bottom of page